Stephanie de Bono

TL;DR: Baricitinib plus remdesivir was superior to remdes Vivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation.

TL;DR: In patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab.

TL;DR: In patients with rheumatoid arthritis and an inadequate response to biologic DMARDs, baricitinib at a daily dose of 4 mg was associated with clinical improvement at 12 weeks and a small reduction in neutrophil levels and increases in serum creatinine and low-density cholesterol levels.

TL;DR: The baricitinib 4 mg dose, but not the 2mg dose, significantly improved the signs and symptoms of active systemic lupus erythematosus in patients who were not adequately controlled despite standard of care therapy, with a safety profile consistent with previous studies of baricit inib.

TL;DR: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties as discussed by the authors, which has been shown to reduce mortality in hospitalised adults with COVID-19.